Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

343 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Mahon FX, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, Martinez-Lopez J, Vestergaard H, Ehrencrona H, Machová Poláková K, Olsson-Strömberg U, Ossenkoppele G, Berger MG, Etienne G, Dengler J, Brümmendorf TH, Burchert A, Réa D, Rousselot P, Nicolini FE, Hofmann WK, Richter J, Saussele S; EURO-SKI Investigators. Mahon FX, et al. Among authors: brummendorf th. J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647. Online ahead of print. J Clin Oncol. 2024. PMID: 38471049
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S. Rajala HLM, et al. Among authors: brummendorf th. J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23. J Cancer Res Clin Oncol. 2017. PMID: 28337541
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ, Rea D, Rosti G, Cross NCP, Steegmann JL, Griskevicius L, le Coutre P, Coriu D, Petrov L, Ossenkoppele GJ, Mahon FX, Saussele S, Hellmann A, Koskenvesa P, Brümmendorf TH, Gastl G, Castagnetti F, Vincenzi B, Haenig J, Hochhaus A. Giles FJ, et al. Among authors: brummendorf th. J Cancer Res Clin Oncol. 2017 Aug;143(8):1585-1596. doi: 10.1007/s00432-017-2402-x. Epub 2017 Mar 31. J Cancer Res Clin Oncol. 2017. PMID: 28364360 Free PMC article. Clinical Trial.
Effect of ABCG2, OCT1, and ABCB1 (MDR1) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial.
Rinaldetti S, Pfirrmann M, Manz K, Guilhot J, Dietz C, Panagiotidis P, Spiess B, Seifarth W, Fabarius A, Müller M, Pagoni M, Dimou M, Dengler J, Waller CF, Brümmendorf TH, Herbst R, Burchert A, Janβen C, Goebeler ME, Jost PJ, Hanzel S, Schafhausen P, Prange-Krex G, Illmer T, Janzen V, Klausmann M, Eckert R, Büschel G, Kiani A, Hofmann WK, Mahon FX, Saussele S. Rinaldetti S, et al. Among authors: brummendorf th. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):266-271. doi: 10.1016/j.clml.2018.02.004. Epub 2018 Feb 8. Clin Lymphoma Myeloma Leuk. 2018. PMID: 29510895 Free article. Clinical Trial.
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia.
Bouillon AS, Ventura Ferreira MS, Awad SA, Richter J, Hochhaus A, Kunzmann V, Dengler J, Janssen J, Ossenkoppele G, Westerweel PE, Te Boekhorst PAW, Mahon FX, Hjorth-Hansen H, Isfort S, Fioretos T, Hummel S, Schemionek M, Wilop S, Koschmieder S, Saußele S, Mustjoki S, Beier F, Brümmendorf TH. Bouillon AS, et al. Among authors: brummendorf th. Blood Adv. 2018 Jul 10;2(13):1572-1579. doi: 10.1182/bloodadvances.2018017772. Blood Adv. 2018. PMID: 29980572 Free PMC article. Clinical Trial.
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M. Machova Polakova K, et al. Among authors: brummendorf th. Leukemia. 2024 Feb;38(2):318-325. doi: 10.1038/s41375-023-02109-2. Epub 2023 Dec 21. Leukemia. 2024. PMID: 38129513 Free PMC article.
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line.
Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. Kreutzman A, et al. Among authors: brummendorf th. Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210. eCollection 2019. Oncoimmunology. 2019. PMID: 31428530 Free PMC article.
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, Fabisch C, Brümmendorf TH, Burchert A, le Coutre P, Krause SW, Saussele S, Safizadeh F, Pfirrmann M, Hochhaus A, Ernst T. Schönfeld L, et al. Among authors: brummendorf th. Leukemia. 2022 Sep;36(9):2242-2249. doi: 10.1038/s41375-022-01648-4. Epub 2022 Jul 28. Leukemia. 2022. PMID: 35902731 Free PMC article.
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Michel C, Burchert A, Hochhaus A, Saussele S, Neubauer A, Lauseker M, Krause SW, Kolb HJ, Hossfeld DK, Nerl C, Baerlocher GM, Heim D, Brümmendorf TH, Fabarius A, Haferlach C, Schlegelberger B, Balleisen L, Goebeler ME, Hänel M, Ho A, Dengler J, Falge C, Möhle R, Kremers S, Kneba M, Stegelmann F, Köhne CH, Lindemann HW, Waller CF, Spiekermann K, Berdel WE, Müller L, Edinger M, Mayer J, Beelen DW, Bentz M, Link H, Hertenstein B, Fuchs R, Wernli M, Schlegel F, Schlag R, de Wit M, Trümper L, Hebart H, Hahn M, Thomalla J, Scheid C, Schafhausen P, Verbeek W, Eckart MJ, Gassmann W, Schenk M, Brossart P, Wündisch T, Geer T, Bildat S, Schäfer E, Hasford J, Hehlmann R, Pfirrmann M. Michel C, et al. Among authors: brummendorf th. Haematologica. 2019 May;104(5):955-962. doi: 10.3324/haematol.2018.206797. Epub 2018 Dec 4. Haematologica. 2019. PMID: 30514803 Free PMC article. Clinical Trial.
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators. Hochhaus A, et al. Among authors: brummendorf th. Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22. Leukemia. 2020. PMID: 32572189 Free PMC article. Clinical Trial.
343 results